Metformin Use Linked to Lower Bladder Cancer Risk: Meta-Analysis of 6.3 Million People with Diabetes
Pooled data from 14 observational studies (~6.3M people with T2DM): metformin associated with lower bladder cancer incidence (RR 0.67, 95% CI 0.46–0.98); pioglitazone and SGLT2 inhibitors showed no significant association.
By Sanare Lab · September 23, 2026 · 1 min read
Key Takeaway
A PRISMA meta-analysis of 14 observational studies (~6.3 million people with type 2 diabetes) links metformin use to a one-third lower relative risk of bladder cancer (RR 0.67; 95% CI 0.46–0.98). The evidence is observational — an association, not proof of prevention.
Type 2 diabetes carries an increased bladder-cancer risk, and which glucose-lowering drugs modify that risk has been debated for years. A systematic review by Mathez et al. (Urologia, September 17, 2026) pooled the available observational evidence to answer it.
The Numbers
Metformin: pooled RR 0.67 (95% CI 0.46–0.98) — significantly lower risk, with substantial between-study heterogeneity. Pioglitazone: RR ≈1.05 (0.52–2.09), I²=99% — no clear association overall. SGLT2 inhibitors: RR 0.98 (0.70–1.37) — no increased-risk signal. For context on how repurposed drugs are dosed in practice, see our dosing calculator; background on the Care Oncology Protocol and on metformin–ivermectin breast-cancer data is available in our long-reads.
References
- Mathez W, Vincentelli A, Chaoui I, Bruyère F, Bourgi A. Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis. Urologia. 2026 Sep 17. doi:10.1177/03915603261486088. PMID: 42755180.
Medical Disclaimer
This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. The study described is a meta-analysis of observational data on cancer risk in people with type 2 diabetes — not a treatment trial, and not a basis for starting, stopping or changing any medication. Always consult a licensed healthcare provider before making decisions about any drug or supplement, especially if you have a medical condition or are undergoing treatment.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.